KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cadre Holdings (CDRE) Asset Writedowns and Impairment (2020 - 2025)

Cadre Holdings' Asset Writedowns and Impairment history spans 6 years, with the latest figure at -$230000.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 1816.67% year-over-year to -$230000.0; the TTM value through Sep 2025 reached -$183000.0, down 123.28%, while the annual FY2024 figure was $764000.0, 1057.58% up from the prior year.
  • Asset Writedowns and Impairment reached -$230000.0 in Q3 2025 per CDRE's latest filing, down from $57000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $480000.0 in Q1 2024 to a low of -$230000.0 in Q3 2025.
  • Average Asset Writedowns and Impairment over 5 years is $45736.8, with a median of $40000.0 recorded in 2023.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 1100.0% in 2024, then tumbled 1816.67% in 2025.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $66000.0 in 2021, then surged by 160.61% to $172000.0 in 2022, then tumbled by 83.14% to $29000.0 in 2023, then crashed by 75.86% to $7000.0 in 2024, then plummeted by 3385.71% to -$230000.0 in 2025.
  • Per Business Quant, the three most recent readings for CDRE's Asset Writedowns and Impairment are -$230000.0 (Q3 2025), $57000.0 (Q2 2025), and -$17000.0 (Q1 2025).